Recombinant Sheep Pox Virus Proteins Elicit Neutralizing Antibodies

Area of Science:

• Veterinary Virology
• Immunology
• Vaccine Development

Background:

• Sheep pox disease, caused by sheep pox virus (SPPV), poses a significant threat to livestock.
• Current control methods are limited, necessitating the development of effective vaccines.
• Subunit vaccines offer a safer alternative to traditional live attenuated vaccines.

Purpose of the Study:

• To assess the immunogenicity and neutralizing capacity of specific SPPV structural proteins.
• To identify potential candidate antigens for a novel sheep pox subunit vaccine.
• To investigate the feasibility of using recombinant proteins for SPPV control.

Main Methods:

• Identification of SPPV structural proteins through sequence homology with vaccinia virus (VACV).
• Production of four SPPV proteins (SPPV-ORF 060, 095, 117, 122) in Escherichia coli.
• Evaluation of antigenic and immunogenic properties using Western blot and antibody production in rabbits.
• Assessment of virus-neutralizing activity in lamb kidney cell cultures.

Main Results:

• SPPV-060, SPPV-095, SPPV-117, and SPPV-122 proteins demonstrated antigenic and immunogenic properties.
• Polyclonal antisera against SPPV-060, SPPV-117, and SPPV-122 exhibited significant virus-neutralizing activity against SPPV.
• This is the first report of virus-neutralizing activity for antisera raised to these specific SPPV proteins.

Conclusions:

• SPPV structural proteins SPPV-060, SPPV-117, and SPPV-122 are promising candidates for subunit vaccine development.
• The identified proteins elicit neutralizing antibodies, crucial for controlling sheep pox virus infection.
• Further research into these candidates could lead to a safe and effective vaccine against sheep pox disease.